About Abl Bio-Technologies Limited
Data last updated: 08 March 2026
Abl Bio-Technologies Limited is a public limited company based in Chennai, Tamil Nadu, India. It specialises in biotechnology, a part of the broader life sciences sector. Incorporated on 16 March 1992, the company has been in operation for over 34 years.
Registered with ROC Chennai under CIN L52599TN1992PLC022340. Listed.
Capital: an authorised share capital of ₹20 Cr and a paid-up capital of ₹8.2 Cr. It is led by directors including Subramanian Gopalakrishnan and Kollenmareth Oomman Isaac.
Last AGM: 28 September 2012. Financial statements filed for year ended 31 March 2012. Office: No.71 Nehru Nagar 2Nd Link Street Industrial Estate Kottivakkam, Chennai, Tamil Nadu, India – 600096.
The company is associated with 2 brands - Abl Biotechnologies, Abl Bio. As per MCA filings, the company has open charges of ₹8.44 Cr and satisfied charges of ₹7.5 Cr on record.
The current compliance status is marked as active non-compliant by the Registrar of Companies. For more details, the company can be reached via its website ablbio.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media**************
-
Registered AddressNo.71 Nehru Nagar 2Nd Link Street Industrial Estate Kottivakkam, Chennai, Tamil Nadu, India – 600096
-
IndustryLife Sciences, Biotechnology
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Abl Bio-Technologies Limited
Abl Bio-Technologies Limited operates two associated brands: ABL Biotechnologies and ABL Bio. These brands represent Abl Bio-Technologies Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| ABL Bio is engaged in developing biopharmaceuticals for critical diseases. | ablbio.com | |
| Biochemicals from marine microbes for the application in pharmaceuticals, nutritional, and cosmetic industries | ablbiotechnologies.com |
Competitors & Alternatives of Abl Bio-Technologies Limited
Brands and companies operating in the same space as Abl Bio-Technologies Limited include argenx, Hummingbird Bioscience, Laurus Labs and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
argenx
|
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | Ghent, Belgium, Belgium | 2008 |
Hummingbird Bioscience
|
Antibody drugs for cancer treatment are developed. | Singapore, Singapore, Singapore | 2015 |
Laurus Labs
|
Pharmaceutical and biotechnology company | Hyderabad, India, India | 2005 |
Lyell Immunopharma
|
CAR-T and TIL immunotherapies for solid tumors are developed. | San Francisco, United States, United States | 2018 |
GigaGen
|
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | San Francisco, United States, United States | 2011 |
Zai Lab
|
Antibody-based therapies for cancers and inflammatory diseases are developed. | Shanghai, China, China | 2013 |
Symbiotec
|
Non-sterile steroid hormone-based APIs and intermediates are manufactured. | Indore, India, India | 2002 |
MacroGenics
|
A biopharmaceutical company focused on cancer therapeutics development. | Rockville, United States, United States | 2000 |
Alexion
|
Therapies for rare and devastating diseases are developed by Alexion. | Zurich, Switzerland, Switzerland | 1992 |
TScan Therapeutics
|
T cell-based treatments for immunological and oncological disorders are developed. | Boston, United States, United States | 1995 |
Board of Directors of Abl Bio-Technologies Limited
Abl Bio-Technologies Limited is currently managed by 3 directors, with 4 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Subramanian Gopalakrishnan | Director | 30 Oct 2003 | 22 Years 8 Months | Current |
|
Kollenmareth Oomman Isaac
Also directs:
Falma Laboratories Private Limited
|
Managing Director | 16 Mar 1992 | 34 Years 3 Months | Current |
| Sankaran Nampoothiri Velliyod Madhavan | Director | 13 Dec 2008 | 17 Years 6 Months | Current |
Financials of Abl Bio-Technologies Limited FY 2012 filings available
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Charges & Borrowings of Abl Bio-Technologies Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 Jan 2008 | International Asset Reconstruction Company Private Limited | ₹30 Lakh | Open |
| 01 Dec 2007 | International Asset Reconstruction Company Private Limited | ₹4.6 Cr | Open |
| 21 Dec 2005 | Sbi Facotrs & Commercial Services Private Ltd | ₹95 Lakh | Open |
| 31 Dec 1997 | Technology Development Board (Dept. of Scien. & Tech.) | ₹1.79 Cr | Open |
| 29 Jun 1995 | Industrial Development Bank of India | ₹50 Lakh | Open |
Total charge records: 8 View all charges
Employees and EPFO Compliance at Abl Bio-Technologies Limited
View historical data on people associated with Abl Bio-Technologies Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Abl Bio-Technologies Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Abl Bio-Technologies Limited
GSTIN & GST Filing Data of Abl Bio-Technologies Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Abl Bio-Technologies Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Abl Bio-Technologies Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Abl Bio-Technologies Limited
MSME Payment Delays by Abl Bio-Technologies Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Abl Bio-Technologies Limited
Subsidiaries & Group Companies of Abl Bio-Technologies Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Abl Bio-Technologies Limited with ownership details.
MCA Filings & Documents of Abl Bio-Technologies Limited
MCA Filings & Documents of Abl Bio-Technologies Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Abl Bio-Technologies Limited
Recent News on Abl Bio-Technologies Limited
Frequently Asked Questions about Abl Bio-Technologies Limited
Abl Bio-Technologies Limited is an active public limited company in the life sciences sector based in Chennai, Tamil Nadu, India. It was incorporated on 16 March 1992 (34+ years old) and is registered under CIN L52599TN1992PLC022340.
The current directors of Abl Bio-Technologies Limited are:
The primary industry of Abl Bio-Technologies Limited is life sciences. The company specifically operates in biotechnology. The company is currently active in this sector.
Yes, Abl Bio-Technologies Limited is a listed company.
Abl Bio-Technologies Limited can be reached at the registered office: No.71 Nehru Nagar 2Nd Link Street Industrial Estate Kottivakkam, Chennai, Tamil Nadu, India – 600096, or through the website ablbio.com.
The authorised capital is ₹20 Cr, and the paid-up capital is ₹8.2 Cr.